Kiniksa Pharmaceuticals Ltd (KNSA)

Drugs • Health Care

Stock AI

News & Reports

July 28, 2026 Kiniksa Pharmaceuticals Ltd. Reports Impressive Q2 2026 Results Kiniksa Pharmaceuticals Ltd. reported impressive Q2 2026 results with revenues reaching $243.6 million, a 55% increase from the previous year. The company continues to invest in its product pipeline, including ARCALYST and new candidates like KPL-387, positioning itself for future growth despite industry challenges.

April 28, 2026 Kiniksa Pharmaceuticals Ltd.: Q1 2026 Financial Report Highlights Kiniksa Pharmaceuticals Ltd. reported a strong Q1 2026 with net revenues of $214.3 million, driven by ARCALYST sales. The company is advancing its product pipeline while maintaining robust liquidity and strategic partnerships.

February 24, 2026 Kiniksa Pharmaceuticals Ltd. 2025 Annual Report: A Year of Growth and Innovation Kiniksa Pharmaceuticals' 2025 annual report highlights a 62% revenue increase driven by its primary product, ARCALYST. Despite rising costs, the company reported a net income of $59 million, outlining a positive operational strategy and ongoing commitment to innovation.

October 28, 2025 Kiniksa Pharmaceuticals Ltd. Reports Strong Q3 2025 Financial Results Kiniksa Pharmaceuticals Ltd. reported strong Q3 2025 financial results, with a net income of $18.43 million and significant revenue growth from ARCALYST. The company has strategically shifted focus to promising investigational therapies like KPL-387 while discontinuing less viable projects.

July 29, 2025 Kiniksa Pharmaceuticals Ltd. Reports Strong Growth in Q2 2025 Financials Kiniksa Pharmaceuticals Ltd. achieved a net income of $26.4 million in Q2 2025, a major turnaround from a loss in 2024, driven by robust sales of ARCALYST. The company is poised for future growth with a strong cash position and plans for new clinical trials.

April 29, 2025 Kiniksa Pharmaceuticals Ltd. Reports Strong Q1 2025 Financial Performance Kiniksa Pharmaceuticals Ltd. reported a net income of $8.5 million in Q1 2025, reversing last year's losses. Growth was driven by ARCALYST sales, which reached $137.8 million. The company maintains a robust financial position, supporting future developments.

February 25, 2025 Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis Kiniksa Pharmaceuticals has announced its development program for KPL-387, a monoclonal antibody aimed at treating recurrent pericarditis. The drug shows promise with a monthly dosing regimen, enhancing patient compliance. The company is also advancing its broader corporate strategy focused on cardiovascular diseases.

February 25, 2025 Kiniksa Pharmaceuticals Ltd. 2024 Annual Report: A Year of Growth Amidst Challenges Kiniksa Pharmaceuticals' 2024 annual report highlights impressive revenue growth to $423.2 million, despite increased operational costs and some product development setbacks. The company remains focused on advancing its innovative therapies while navigating challenges ahead.

February 25, 2025 Kiniksa Pharmaceuticals Reports Strong Q4 and Full Year 2024 Results Kiniksa Pharmaceuticals has reported impressive financial results for Q4 and the full year 2024, with a 79% increase in ARCALYST sales. The company is expanding its product pipeline with new therapies for cardiovascular diseases and has a solid cash position for future growth.

February 20, 2025 Kiniksa Pharmaceuticals Set to Release Q4 and Full Year 2024 Financial Results Kiniksa Pharmaceuticals will hold a conference call on February 25, 2025, to discuss its Q4 and full year 2024 financial results. The event will provide insights into the company's performance, future strategies, and advancements in biopharmaceutical innovations.

January 30, 2025 SWOT Analysis of Kiniksa Pharmaceuticals Ltd in 2025 This SWOT analysis of Kiniksa Pharmaceuticals Ltd for 2025 outlines the company's strengths in product offerings and strategic partnerships, alongside weaknesses such as reliance on third-party manufacturers. The article also discusses opportunities for growth through new indications and threats from competition and regulatory changes.

October 29, 2024 Kiniksa Pharmaceuticals Ltd. Reports Strong Growth in Q3 2024 Financial Results Kiniksa Pharmaceuticals Ltd. reported a substantial increase in Q3 2024 revenue, primarily from ARCALYST sales. The company continues to invest in R&D and strategic partnerships to enhance its product portfolio and market presence.

July 25, 2024 Kiniksa Pharmaceuticals Ltd. Reports Impressive Growth in Q2 2024 Financials Kiniksa Pharmaceuticals Ltd. reported impressive Q2 2024 financial results with $103.4 million in revenue, a significant increase of 89.7% year-over-year. Despite rising operational costs, the company is well-positioned for future growth with strong cash reserves and ongoing product development initiatives.

April 25, 2024 Kiniksa Pharmaceuticals Ltd. Reports Strong Q1 2024 Financial Results Kiniksa Pharmaceuticals reported significant growth in Q1 2024, with ARCALYST sales reaching $78.9 million. Despite rising expenses and a net loss, the company maintains a strong liquidity position and a promising outlook for future growth.

SWOT Analysis of Kiniksa Pharmaceuticals Ltd in 2025

Last updated: January 30, 2025

This SWOT analysis provides a comprehensive overview of Kiniksa Pharmaceuticals Ltd, assessing its strengths, weaknesses, opportunities, and threats as of 2025. As a biopharmaceutical company focused on treating serious diseases, understanding these elements is crucial for navigating the competitive landscape.

Strengths

Strong product portfolio with ARCALYST approved for recurrent pericarditis and CAPS.
Established partnerships with Regeneron and Huadong Pharmaceutical enhancing market reach.
Robust patent protection for innovative drug candidates provides competitive advantages.
Experienced management team with a strategic focus on unmet medical needs.
Patient-centric approach through Kiniksa OneConnect™ improves patient experience and adherence.

Weaknesses

Dependence on third-party manufacturers poses risks for supply chain stability.
Limited product portfolio may restrict revenue streams compared to larger competitors.
High operational costs and historical operating losses creating financial pressure.
Challenges in recruiting and retaining qualified personnel may hinder growth.
Potential issues with coverage and reimbursement affecting product accessibility.

Opportunities

Expansion of ARCALYST into new indications could drive revenue growth.
Continued development of abiprubart and mavrilimumab for broader autoimmune market.
Strategic partnerships can enhance research capabilities and market penetration.
Increasing demand for innovative therapies in underserved medical conditions.
Potential for capitalizing on the growing focus on personalized medicine and immunotherapy.

Threats

Intense competition from existing and emerging therapies in the biopharmaceutical sector.
Risk of regulatory changes impacting product approval and market access.
Economic downturns and stock market volatility affecting financial stability.
Cybersecurity threats and data privacy concerns could disrupt operations.
Legal risks from potential intellectual property litigation impacting market position.

Kiniksa Pharmaceuticals Ltd is positioned with several strengths, including a solid product portfolio and strategic partnerships, but it also faces challenges related to reliance on third-party manufacturers and financial sustainability. The company has significant opportunities for growth through product expansion and innovation, but it must remain vigilant against competitive and regulatory threats to capitalize on these opportunities.

You may also be interested in: